Biscayne Neurotherapeutics' Acquisition

Biscayne Neurotherapeutics was acquired by Supernus Pharmaceuticals on September 13, 2018.

Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing therapies for difficult-to-treat neurological disorders. Biscayne's lead compound, BIS-001, is in clinical development f…

Articles about Biscayne Neurotherapeutics' Acquisition: